We are a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields. Our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. We have ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer. Headquartered in Switzerland, Novocure has U.S. operations in Portsmouth, New Hampshire, Chesterbrook, Pennsylvania and New York City. Additionally, Novocure has offices in Canada, Germany, Jersey, Japan and Israel.
View Top Employees from NovocureWebsite | http://www.novocure.com |
Ticker | NVCR |
Revenue | $248 million |
Funding | $308 million |
Employees | 1,368 (1,289 on RocketReach) |
Founded | 2000 |
Phone | +44 1534 756700 |
Technologies |
JavaScript,
HTML,
PHP
+85 more
(view full list)
|
Industry | Medical Device, Medical Equipment Manufacturing, Medical Devices & Equipment, Health Care, Manufacturing, Oncology, Therapeutics, Cancer, Glioblastoma, Neuro-Oncology |
Web Rank | 856461 |
Web Visits | 69240 |
Keywords | Cancer Treatment, Advanced Cancer Care |
Competitors | Clovis Oncology, Raptor Pharmaceuticals, Sirtex Medical Limited, Sorrento Therapeutics, Inc., Spectrum Pharmaceuticals, Inc. |
SIC | SIC Code 384 Companies, SIC Code 38 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 325414 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 33 Companies |
Looking for a particular Novocure employee's phone or email?
The Novocure annual revenue was $248 million in 2024.
1,289 people are employed at Novocure.
The NAICS codes for Novocure are [3254, 325414, 32541, 32, 325, 33].
The SIC codes for Novocure are [384, 38].